Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Could you contrast the growth rates in proactive and reactive work this quarter and share the current proportion of reactive work in your portfolio? A: Growth in the reactive business was in the low single digits, offset by a slight decline in proactive services. Currently, about 60% of our work is reactive, with 80% to 90% of that being litigation or dispute-driven.
Q: Have you seen any changes in the pace of proactive work across certain markets recently, particularly with supply chain changes? A: Supply chain disruptions and decisions about using different materials can impact product reliability and safety. Clients are exploring diversification strategies, and we are positioning ourselves to assist them. We have seen some increased demand for evaluations and testing in new manufacturing environments, particularly in life sciences and medical devices.
Q: Could you unpack the second quarter outlook further, especially regarding utilization and any areas of softness? A: Utilization is slightly below last year, partly due to the July 4th holiday. Some areas, like life sciences, are experiencing delays in regulatory processes, and there are uncertainties in proactive testing for consumer products. These factors have impacted forecasts by 100 to 200 basis points.
Q: How do you view the potential impact of macroeconomic factors on customer decision-making? A: While macroeconomic factors like tariffs can impact industries, 60% of our work is reactive and necessary regardless of economic conditions. Proactive work in regulated industries like utilities and chemicals will continue despite disruptions. We have a diverse portfolio that helps us navigate challenging times.
Q: How are you approaching FTE growth in the current environment, and what areas are you focusing on for hiring? A: We are hiring strategically in areas with increasing demand, such as automated vehicles, asset risk, and digital health. We expect to be about 4% ahead in headcount by year-end, closing the gap from the start of the year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.